Dr. Mark Moasser (https://www.trapelohealth.com/breast-cancer-clinical-trials), a physician-scientist and breast cancer specialist at the University of California, San Francisco discusses his research focus on the HER2 oncogene, the latest trial findings and the importance of improving patient access to clinical trials.
At Trapelo, connecting oncologists with patient-appropriate clinical trials (https://www.trapelohealth.com/for-oncologists) is a major part of our mission, so we were grateful for the opportunity to talk to Dr. Moasser and learn more about his thoughts on this matter. Tune in to the full episode to learn more about his current research and perspective on the future of precision medicine.
Podden och tillhörande omslagsbild på den här sidan tillhör Trapelo. Innehållet i podden är skapat av Trapelo och inte av, eller tillsammans med, Poddtoppen.
